Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494
Citius Oncology made less money than people expected—their sales were about $1 million short of the goal. When a company sells less than predicted, it's a sign to watch whether they can catch up or if there's a bigger problem.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.